| # | Drug | Count |
|---|---|---|
| 0 | OXALIPLATIN | 55 |
| 1 | FLUOROURACIL | 38 |
| 2 | FLUOROURACIL CREAM, 0.5% | 38 |
| 3 | PANITUMUMAB | 34 |
| 4 | BEVACIZUMAB | 25 |
| 5 | CAPECITABINE | 20 |
| 6 | ACETAMINOPHEN | 15 |
| 7 | PEMBROLIZUMAB | 15 |
| 8 | ACETAMINOPHEN 500MG | 14 |
| 9 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 14 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PANITUMUMAB | 34 | 0.0021 |
| 1 | FRUQUINTINIB | 6 | 0.0015 |
| 2 | BEVACIZUMAB-BVZR | 1 | 0.0014 |
| 3 | DARIFENACIN HYDROBROMIDE | 1 | 0.0012 |
| 4 | NITISINONE | 1 | 0.0010 |
| 5 | METYRAPONE | 1 | 0.0010 |
| 6 | INFLIXIMAB-AXXQ | 1 | 0.0009 |
| 7 | ANAGRELIDE HYDROCHLORIDE | 1 | 0.0009 |
| 8 | ALPROSTADIL | 3 | 0.0008 |
| 9 | PENTAMIDINE ISETHIONATE | 1 | 0.0008 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 1 | 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC] | 1 | 0.0012 |
| 2 | Adrenal Steroid Synthesis Inhibitor [EPC] | 1 | 0.0010 |
| 3 | Epidermal Growth Factor Receptor Antagonist [EPC] | 47 | 0.0010 |
| 4 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 5 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 15 | 0.0003 |
| 6 | Platinum-based Drug [EPC] | 64 | 0.0002 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 58 | 0.0002 |
| 8 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 20 | 0.0002 |
| 9 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |